Moderna, Inc. - Common Stock (MRNA)
34.28
+1.49 (4.54%)
NASDAQ · Last Trade: Jul 10th, 8:51 PM EDT
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office?
Amidst rising public distrust and a series of high-profile investigations into lawmakers' financial dealings, calls to ban or heavily restrict stock
Via MarketMinute · July 10, 2025
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.
Via Benzinga · July 10, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 3.8% in the morning session after the U.S. Food and Drug Administration (FDA) granted full approval for its Spikevax COVID-19 vaccine to be used in children. The approval covers children from six months through 11 years of age who are at an elevated risk for severe COVID-19.
Via StockStory · July 10, 2025
The vaccine was previously available for pediatric populations under Emergency Use Authorization only.
Via Stocktwits · July 10, 2025
Wall Street Holds Its Breath: Tariff Tantrums, Solar Slaps, and a Surge from Moderna
Via Chartmill · July 9, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.
Via Chartmill · July 8, 2025
Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant individuals.
Via Benzinga · July 8, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · July 8, 2025
Via Benzinga · July 8, 2025
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.
Via Stocktwits · July 8, 2025
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.
Via Benzinga · July 3, 2025
The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.
Via Stocktwits · July 2, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
Via Chartmill · July 2, 2025
The new Health Secretary reportedly recommended Moderna's RSV vaccine for a broader group of adults.
Via Investor's Business Daily · July 2, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · July 2, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
Via Chartmill · July 1, 2025
Shares have long struggled, but things could be looking up for Moderna stock in the face of new flu shot results.
Via Investor's Business Daily · June 30, 2025
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.
Via Benzinga · June 30, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · June 30, 2025
The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate.
Via Stocktwits · June 30, 2025